Live tape
Top 8, mentions 7d10,066TSLA2,067 mentions▲ +0.05GOOGL1,609 mentions▲ +0.04NVDA1,230 mentions▲ +0.07CRWV1,216 mentions▲ +0.03SPCX1,103 mentions▲ +0.07QQQ1,076 mentions▲ +0.04META891 mentions▲ +0.05NBIS874 mentions▲ +0.06

Equity · Healthcare

EWTX

NASDAQ

Edgewise Therapeutics, Inc.

$40 +4.77% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for EWTX to draw a line in its place.

Track this symbol on TradingView TradingView chart
Market cap $4.3B
52-week range $12.66 – $48
Avg volume 344.7K

as of Jul 17, 2026

EWTX insider trades

SEC Form 4

EWTX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 19 November 2025.

Date Insider Type Shares Value
12 Nov 2025 Russell Alan J Chief Scientific Officer Sell 100,000 $2.11M
11 Nov 2025 Fox Jonathan C Buy 10,700 $199K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
19 Nov 2025 Martin Christopher Nathan Award 45,150
12 Nov 2025 Russell Alan J Chief Scientific Officer Option exercise 100,000 $18K
10 Nov 2025 Nofi Michael Chief Financial Officer Award 306,250
01 Oct 2025 Fox Jonathan C Award 728

EWTX reported financials

SEC EDGAR XBRL SEC EDGAR

EWTX reported net income of −$167.8M for the fiscal year ended 31 Dec 2025.

Figure Reported Period
Net income −$167.8M 31 Dec 2025 fiscal year
Diluted EPS −$1.63 31 Dec 2025 fiscal year
Total assets $479.7M 30 Jun 2026 at period end
Total equity $448.1M 30 Jun 2026 at period end

EWTX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.53 —
31 Mar 2026 Q1 2026 −$0.46 —
31 Dec 2025 FY 2025 −$1.63 —
30 Sep 2025 Q3 2025 −$0.39 —
30 Jun 2025 Q2 2025 −$0.34 —
31 Mar 2025 Q1 2025 −$0.43 —
31 Dec 2024 FY 2024 −$1.45 —
30 Sep 2024 Q3 2024 −$0.36 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

EWTX institutional holders

SEC Form 13F SEC EDGAR

8 of the 45 institutional funds we track reported a EWTX position for the quarter ended 30 Jun 2026 — a combined $187.3M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Trimmed −43.7% shares 3,701,719 $150.4M
Citadel Advisors Held (±25%) +9.5% shares 469,707 $19.1M
D. E. Shaw & Co. Added +80.3% shares 189,115 $7.7M
Point72 Asset Management New position 117,262 $4.8M
Tudor Investment Corp Added +90.5% shares 56,934 $2.3M
Two Sigma Investments Held (±25%) −2.6% shares 49,548 $2.0M
AQR Capital Management Added +116.1% shares 18,456 $750K
Marshall Wace Trimmed −99.1% shares 6,100 $248K
Millennium Management Exited

EWTX fails-to-deliver

SEC CNS data SEC

On 09 Sep 2026, 226 shares of EWTX failed to deliver (about $10K).

Settlement date Shares failed Notional % of shares out
09 Sep 2026 226 $10K <0.001%

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings